Results 131 to 140 of about 454,627 (348)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Affinity‐Directed Site‐Specific Protein Labeling and Its Application to Antibody‐Drug Conjugates

open access: yesAdvanced Science
Chemically modified proteins have diverse applications; however, conventional chemo‐selective methods often yield heterogeneously labeled products. To address this limitation, site‐specific protein labeling holds significant potential, driving extensive ...
Sooin Kim   +9 more
doaj   +1 more source

Medicare Part D: Simplifying the Program and Improving the Value of Information for Beneficiaries [PDF]

open access: yes, 2008
Examines options for simplifying Medicare's prescription drug benefit, including streamlining benefit procedures and descriptions; further standardizing benefit parameters, especially cost-sharing rules; and modifying rules on plan ...
Jack Hoadley
core  

Interplay between RNA‐protein interactions and RNA structures in gene regulation

open access: yesFEBS Open Bio, EarlyView.
Methodological advances in mapping transcriptome‐wide RNA‐protein interactions and RNA structures have started to uncover the potential of RNP conformations in gene regulation. Competing RNA–RNA, RNA‐protein and protein–protein interactions shape the compaction and function of RNPs throughout their lifetime and may provide novel therapeutic targets in ...
Jenni Rapakko   +2 more
wiley   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

open access: yesFEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee   +3 more
wiley   +1 more source

Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling. [PDF]

open access: yesJ Gen Intern Med, 2020
Desai B, Hong K, Powers JH, Doshi P.
europepmc   +1 more source

The New Food Safety [PDF]

open access: yes, 2019
A safe food supply is essential for a healthy society. Our food system is replete with different types of risk, yet food safety is often narrowly understood as encompassing only foodborne illness and other risks related directly to food ingestion.
Broad Leib, Emily M., Pollans, Margot J.
core   +1 more source

Long‐term culture of skin biopsies: maintenance of fibroblast production and competency of reprogramming

open access: yesFEBS Open Bio, EarlyView.
Skin biopsies taken from a patient with an ultra‐rare disorder as well as controls were cultured for up to 473 days. The chunks of skin were serially transferred to a new culture plate when confluent with fibroblasts. Different generations of fibroblasts were analyzed for cell and molecular properties, proliferation, and competence for reprogramming to
Sudiksha Rathan‐Kumar   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy